The Dutch Protocol: The Original Studies and Their Critics

How Dutch clinicians built the puberty-blocker protocol, what the 2011 and 2014 studies found, why critics dispute them, and how practice changed abroad.

Overview

The Dutch protocol is the treatment model that introduced puberty blockers into gender medicine. It was developed in the Netherlands in the 1990s and early 2000s by a small group of clinicians in Utrecht and Amsterdam. Under the protocol, a carefully screened adolescent with lifelong gender dysphoria (distress about the mismatch between their sex and their felt gender) could start a gonadotropin-releasing hormone agonist (GnRHa), a drug that switches off the hormonal signals that drive puberty, from about age 12. Cross-sex hormones followed at about 16 and surgery at 18.

Two follow-up studies of a single Amsterdam cohort, published in 2011 and 2014, became the main evidence that this sequence works. International guidelines cited them, and clinics in the UK, North America, Australia and elsewhere adopted versions of the approach. Since about 2019 the studies have faced sustained criticism. Critics point to their small samples, the people who dropped out, a changed measurement scale, a patient who died after surgery, and the fact that a British attempt to replicate the results found no psychological benefit.

This page traces the protocol from its origins to the newest Dutch data, including van der Loos et al. 2022 on continuing hormones and the Dutch Health Council's 2026 review. It sets detransitioners' accounts of being given blockers young alongside trans accounts of the same treatment. The general evidence on blockers (bone density, brain development, fertility, side effects) is covered on Puberty Blockers. The national evidence reviews that followed are covered on Evidence Reviews. Childhood desistance research, much of which also came from Amsterdam, is on Desistance.

The Dutch studies were the first prospective research on puberty suppression for gender dysphoria. They found improvements in mood and behaviour in a small, highly selected group. They did not include a comparison group, did not follow anyone past their early twenties, and did not study the type of patient who now makes up most referrals in many countries. The Dutch clinicians themselves have said their findings may not apply to that newer group.

Origins of the protocol

Before puberty blockers

Through the 1970s and 1980s, adult "transsexuals" in the Netherlands were treated at gender teams in Amsterdam and Utrecht. Adolescents were generally told to wait until 18 for hormones. Peggy Cohen-Kettenis, a psychologist who had worked with adult patients, moved to the child and adolescent psychiatry department of Utrecht University Medical Centre in 1987. Adolescents with gender dysphoria began to be referred to her. According to a 2024 Amsterdam UMC doctoral thesis that recounts the clinic's history, she noticed that some of them struggled despite psychological support, and pushed to lower the age for cross-sex hormones to 16 for a select group who were "functioning well socially and had supportive parents" (van der Loos 2024, The Dutch Protocol: Coming of Age).

The case for earlier treatment rested on follow-ups of the first 22 young patients from the Utrecht clinic, interviewed in their twenties after surgery, who appeared to do better than adults who had transitioned later. Michael Biggs, an Oxford sociologist who has written the most detailed history of the protocol, notes that this comparison group was drawn from earlier decades of adult patients (Biggs 2023).

The first blocked adolescent

The idea of using GnRHa came from paediatric endocrinology, where the drugs were already used to stop precocious puberty (puberty that starts unusually early). The first published case was a female patient known as "FG" or "B", who began puberty suppression at 13, stayed on it until 18, and then had testosterone and a series of operations: mastectomy, hysterectomy with removal of the ovaries, and genital surgery, the last of which was still pending at age 20 (Cohen-Kettenis & van Goozen 1998). Biggs notes that for several years this single case report was the only published evidence for the intervention. He also notes that it was already being adopted elsewhere, including in the 2001 Standards of Care of the Harry Benjamin International Gender Dysphoria Association, which later became the World Professional Association for Transgender Health (WPATH) (Biggs 2023).

The clinicians

Three names are attached to the protocol: Peggy Cohen-Kettenis, the psychologist Biggs credits as its main inventor; Henriette Delemarre-van de Waal, paediatric endocrinologist at VU University Medical Center (VUmc) in Amsterdam; and Louis Gooren, endocrinologist in the adult gender team, who co-authored the first proposal in print (Gooren & Delemarre-van de Waal 1996).

That 1996 paper described GnRHa as "fully reversible", a claim Biggs argues had no data behind it at the time, given that the protocol meant suppression for up to four years. The protocol was formally written up in 2006 (Delemarre-van de Waal & Cohen-Kettenis 2006) and again in 2008 (Cohen-Kettenis, Delemarre-van de Waal & Gooren 2008). The adolescent service moved to Amsterdam, where the Center of Expertise on Gender Dysphoria at VUmc (now Amsterdam UMC) became the source of most of the research.

The rationale

The protocol rested on two claims: that blockers are reversible (stop the drug and puberty resumes), and that they aid diagnosis by giving "time to think" without the distress of unwanted puberty. A third aim was practical: someone who never goes through their own sex's puberty is easier to make look like the opposite sex later. Biggs argues this cosmetic aim was the real selling point. If almost everyone who starts blockers goes on to cross-sex hormones, the "diagnostic" period does not seem to filter anyone out (see Puberty Blockers: the "pause button" question).

The eligibility rules

The Dutch protocol was never meant for every young person who said they were transgender. The published criteria were strict (Delemarre-van de Waal & Cohen-Kettenis 2006; de Vries et al. 2011):

RuleWhat it requiredWhy it mattered
Early-onset, persistent dysphoriaGender dysphoria present from early childhood, which had become worse with the first physical changes of pubertyThe clinicians' own follow-ups showed that most clinic-referred children's dysphoria faded by adolescence (see Desistance). Dysphoria that lasted into and intensified at puberty was treated as a sign it would persist.
Psychological stabilityNo serious psychiatric conditions that could interfere with assessment or treatment; adolescents with problems such as severe depression or psychosis were to be treated firstTo make sure distress was not caused by something else, and that the young person could cope with treatment
Family supportParents or carers who supported the treatment and could provide stable support throughoutTreatment lasted years and depended on stable home life
Age and puberty stageAt least 12 years old and in Tanner stage 2–3 (the first visible signs of puberty)The clinicians wanted the adolescent to experience the start of their own puberty first, as a diagnostic test
Comprehensive assessmentMany sessions with a mental health professional over a long period before any medical step, and continued psychological supportTo explore other explanations and support decision-making

These criteria excluded a large share of referrals. In the cohort that produced the 2011 and 2014 studies, 140 of 196 consecutively referred adolescents were judged eligible for medical treatment (de Vries et al. 2011). At the Leiden clinic between 2010 and 2018, 143 of 214 adolescents old enough for treatment (67%) were judged suitable for blockers (Brik et al. 2020).

Biggs found that practice did not always match the written rules. The minimum age of 12 was not always observed, and the 2014 paper's own table shows that ages at the start of GnRHa in that cohort ranged from 11.5 to 18.5 (Biggs 2023; de Vries et al. 2014).

Would detransitioners have met the criteria?

The eligibility rules assumed that a careful assessment of early-onset, persistent dysphoria could identify adolescents whose dysphoria would last. Some detransitioners say they would have passed that screening. They describe childhood-onset dysphoria, long assessments and no obvious warning signs, and still detransitioned.

I had been in weekly psychologist sessions since I was 12, had an assessment for gender dysphoria that consited of multiples sessions over the course of 6 months and was diagnosed at age 15... I was a very clear cut case of a strongly dysphoric binary trans guy who fit the diagnostic criteria and didn't flag any warning signs that could indicate a future detransition, and yet here I am. —Wonderful_Walk4093, detrans female

It's funny, it seems like a lot of us here are people who would have formerly been classified as "real trans" people. Dysphoria since childhood, none of the stereotypical signs of future detransition. It really makes you question the whole thing. —malcoze, detrans female

These accounts do not show how often early-onset cases detransition. They do show that the protocol's central assumption, that the right selection criteria can predict who will benefit, is not something detransitioners take for granted. The same Amsterdam team's childhood research found that most clinic-referred children's dysphoria faded, and that childhood dysphoria was strongly linked to later same-sex attraction (Desistance). Biggs argues the protocol never dealt with what blocking puberty means for an adolescent whose dysphoria might otherwise have faded.

The 2011 study: blockers alone

What it did

de Vries et al. 2011, published in the Journal of Sexual Medicine, followed the first 70 of the 111 adolescents prescribed blockers at the Amsterdam clinic between 2000 and 2008. They were assessed before starting GnRHa and again shortly before starting cross-sex hormones, on average about two years later. Measures covered behavioural and emotional problems (parent- and self-reported), depression, anxiety, anger, general functioning as rated by clinicians, gender dysphoria and body satisfaction.

What it found

  • Behavioural and emotional problems and depressive symptoms fell, and clinician-rated functioning improved.
  • The share of adolescents whose parent-reported problems were in the clinical range fell from 44% to 22%.
  • Gender dysphoria and body dissatisfaction did not change. Neither did anxiety or anger.
  • No adolescent stopped blockers. All 70 went on to cross-sex hormones.

The authors concluded that puberty suppression "may be considered a valuable contribution" to treatment.

The limits

  • No comparison group. Improvements could reflect growing up, the psychological support every adolescent received, or regression to the mean (people tend to be assessed when distress is high, so later scores tend to look better whatever happens).
  • Small and incomplete data. For some measures, results were available for only about 41 adolescents, according to the re-analysis by England's National Institute for Health and Care Excellence (NICE), which rated the findings as very low certainty (NICE 2020).
  • Mostly normal scores at the start. The reported changes were mostly shifts within the normal range.
  • The core problem did not improve. The drug is meant to relieve distress about the body, yet the measures of that distress were unchanged.
  • Every patient continued. That 100% continued to hormones can be read as a sign of good selection, or as a sign that the "diagnostic" pause did not work as a pause.

The 2014 study: after hormones and surgery

What it did

de Vries et al. 2014, published in Pediatrics, followed the same cohort to at least one year after surgery. Participants were assessed three times: before blockers (average age 13.6), at the start of cross-sex hormones (16.7), and after surgery (20.7). Surgery meant vaginoplasty for the trans women; for the trans men it meant mastectomy and hysterectomy with removal of the ovaries.

Who was in the final sample

Of the 70 adolescents in the 2011 study, 55 (22 trans women, 33 trans men) took part in the final assessment. The paper lists the 15 who did not:

ReasonNumber
Not yet one year after surgery6
Medically not eligible for surgery (for example uncontrolled diabetes, morbid obesity)3
Refused to take part2
Did not return questionnaires2
Dropped out of care1
Died after vaginoplasty (necrotising fasciitis, a severe tissue infection)1

Eleven of the 15 non-participants were trans women (born male). Complete data across all three time points were available for 40 participants.

What it found

  • Gender dysphoria and body image difficulties persisted through puberty suppression and "remitted" after hormones and surgery.
  • Psychological functioning improved steadily, to rates of clinical problems "indistinguishable from general population samples".
  • Well-being and quality of life were described as similar to or better than same-age Dutch peers.
  • No participant reported regret, and all were "very or fairly satisfied" with their surgeries.

The authors concluded that the protocol gives gender-dysphoric youth "the opportunity to develop into well-functioning young adults". Alongside the 2011 paper, this became the main evidence for the protocol in guidelines such as the Endocrine Society's 2017 guideline and WPATH's Standards of Care.

The critiques

Abbruzzese, Levine and Mason (2023)

In 2023, E. Abbruzzese of the Society for Evidence-Based Gender Medicine (a group critical of youth transition), psychiatrist Stephen Levine and paediatrician Julia Mason published a detailed critique in the Journal of Sex & Marital Therapy (Abbruzzese, Levine & Mason 2023). It was a reply to Annelou de Vries, who had defended the studies against an earlier paper by Levine and colleagues (de Vries 2023).

The authors accept that the studies showed hormones and surgery "can successfully change the phenotypical appearance" of adolescents. They argue the studies did not show psychological benefit large enough to justify the harms, "including the certainty of sterility". Their main points:

  1. Selection bias. Only adolescents who did well enough at each stage moved on to the next and were counted. Those who could not have surgery, did not respond, or dropped out vanished from the results. In their words, the studies "inadvertently reported on only their best-case outcomes". They note a final sample of 55, "with key outcomes available for as few as 32 individuals".
  2. The gender dysphoria scale was switched. The Utrecht Gender Dysphoria Scale (UGDS) has a male and a female version with mostly different items. Before treatment and at the start of hormones, participants filled in the version for their birth sex. After surgery they filled in the version for their identified gender. The paper itself says this. Abbruzzese and colleagues argue that switching to a scale designed for the opposite sex "essentially guarantee[d]" a fall in scores, so the headline finding of "resolution of gender dysphoria" is "entirely invalid".
  3. Confounding by therapy. Every adolescent received ongoing psychological support, so the effects of drugs, therapy and maturation cannot be separated.
  4. Physical harms not measured. The studies did not assess bone, brain or sexual function, although these risks had been raised from the start.
  5. Morbidity and mortality. Counting the death and the patients who could not have surgery for medical reasons, the authors estimate short-term serious morbidity and mortality "may be as high as 6%-7%".
  6. Poor applicability. In the authors' view, the common presentation in clinics today is dysphoria that started after puberty, together with significant mental illness: "two clinical presentations the Dutch explicitly disqualified". The findings therefore cannot be applied to them.

The paper is written by critics of youth transition and should be read as an argument, not a neutral review. But each point can be checked against the original papers, and the facts it relies on (the 55 participants, the scale switch, the death, the excluded patients, the selection rules) come from the Dutch authors' own reporting.

Michael Biggs

Biggs's 2023 history (Biggs 2023) reaches similar conclusions by a different route. He argues that "the number of observations was considerably fewer than 70", that the fall in gender dysphoria "depended on incommensurable scales" (before and after scores came from different questionnaires), and that the outcomes "omit one patient who died because puberty suppression dictated a riskier vaginoplasty". He adds that neither founding claim was ever tested: suppression for four years or more was not shown to leave no lasting effect, and with nearly everyone going on to hormones, the "diagnostic" pause never sorted anyone out. The protocol also ignored the link between childhood dysphoria and later homosexuality, and the effect of suppression on sexual development.

Biggs also compared the Dutch results with early results from the British replication that the Tavistock clinic had presented to its own board in 2015. He reported that the Dutch improvement in psychological functioning was not repeated in England (Biggs 2020), and pointed to signs in those preliminary data of more self-harm and more problems in girls (Carmichael et al. 2021). Those preliminary data were never published in a journal, so they cannot be independently checked.

The post-surgery death

One young trans woman in the cohort died after surgery. Her case was published separately by the Amsterdam surgical team (Negenborn et al. 2017). She had been blocked from early puberty, so her genital tissue had not developed enough for the standard penile-inversion vaginoplasty. Surgeons used a section of intestine instead, a more complex operation. She developed necrotising fasciitis caused by drug-resistant E. coli and died.

The 2014 paper mentions the death in one sentence as a reason for non-participation. Critics argue that a death directly linked to the protocol (early suppression leading to a riskier operation) should have been treated as an outcome of the protocol, not as missing data. The same tissue problem affects other males blocked early; see Vaginoplasty and Sexual Function.

Dropouts and missing data

The Dutch authors reported no statistical differences at baseline between the 55 participants and the 15 non-participants. Critics respond that non-participants are exactly the people whose outcomes matter most for safety, and that "no difference at baseline" says nothing about how they fared later. The same issue runs through the later Dutch studies. In the van der Loos et al. 2023 bone study, only 75 of 143 eligible people (52%) took part. In the clinic's adult cohort, 36% of patients had stopped attending after several years (Wiepjes et al. 2018).

Detransitioners often raise this point from their own experience. Several say they simply stopped going to the clinic and would never have been recorded as detransitioned.

I never talked to the doctor at the gender clinic ever again after I stopped hormones so how would they even know I detransitioned? —Lurkersquid, detrans female

I also signed papers that mean I'm included in some study but I'm pretty sure they don't put me in as a detrans person now. So I'm unsure how real these studies can be. So many detrans people just ghost their clinics because they have trauma associated with them and don't want to go back to them. —ClydeFallon, detrans female

The UK replication: Carmichael et al. (2021)

The Tavistock's Gender Identity Development Service (GIDS) in London started an "Early Intervention Study" in 2011. It was designed to replicate the Dutch approach in 12–15-year-olds with severe, persistent dysphoria, using similar entry criteria: lifelong dysphoria, psychological stability and at least six months of assessment (Carmichael et al. 2021).

Amsterdam (de Vries et al. 2011)London (Carmichael et al. 2021)
Sample70 of 111 treated, 2000–200844, started 2011–2015
Comparison groupNoneNone
Psychological problemsImprovedNo change (parent and self report)
Self-harmNot reported separatelyNo change on average
Gender dysphoriaNo changeNo change
Went on to cross-sex hormones70 of 70 (100%)43 of 44 (98%)
Data at later time pointsAbout 41–70 depending on the measure24 at 2 years, 14 at 3 years

The authors found "no changes in psychological function, quality of life or degree of gender dysphoria". Bone density fell behind peers, and side effects such as headaches, hot flushes and tiredness were common. The study was not published in a journal until 2021, ten years after it began; Biggs argues the delay reflected its disappointing results. A 2024 re-analysis of the published data looked at each individual instead of group averages. It found that 15–34% of young people "reliably deteriorated", depending on the measure and time point (McPherson & Freedman 2024).

The most direct attempt to repeat the Dutch study, with similar selection rules, therefore did not reproduce its psychological benefits. A later US study of 94 youth starting blockers also found no measurable change in mental health over two years, with 37% of depression data missing at follow-up (Olson-Kennedy et al. 2025; see Olson-Kennedy NIH Study).

The Dutch response

The Dutch clinicians have not withdrawn the studies. In her reply to Levine and colleagues, de Vries argued that critics had misunderstood the research, that later shorter-term studies also showed improved or stable psychological functioning and relief of gender incongruence, and that careful evaluation and informed consent had always been recommended (de Vries 2023). The broader Dutch position, repeated by the Dutch Health Council and government in 2026, is that problems found abroad (for example by the Cass Review in England) come from clinics that did not follow the Dutch model, and so do not apply to Dutch care (Ministry of Health, Welfare and Sport 2026).

How clinics worldwide departed from the criteria

The Dutch protocol spread quickly. In most places the drugs and the age thresholds were adopted, but the eligibility rules were loosened or dropped.

The patient population changed

From around 2012, referrals to youth gender clinics rose sharply in many countries, and the majority shifted to adolescent females. Many had no childhood history of dysphoria and had other mental health problems. In Finland's first youth gender service, 41 of 47 adolescents assessed in 2011–2013 (87%) were born female, 75% had previously been in specialist psychiatric care for other reasons, and 64% had no gender dysphoria in childhood that they or their parents could recall (Kaltiala-Heino et al. 2015). These are the two groups — post-pubertal onset and significant psychiatric problems — that the Dutch criteria excluded. See Demographic Shift and Rapid-Onset Gender Dysphoria.

England

At GIDS, blockers were first given only within the Early Intervention Study. The Cass Review 2024 found that from 2014, before any results were available, blockers "moved from a research-only protocol to being available in routine clinical practice". They were given to a broader group of patients who would not have met the original entry criteria. The review also found that assessment had been inconsistent and that other explanations for distress, such as autism and trauma, were often not explored. See The Tavistock GIDS and Bell v Tavistock.

Guidelines

  • The Endocrine Society's 2017 guideline recommended blockers at the first signs of puberty. By its own grading, the evidence behind every adolescent recommendation was low or very low quality. See Endocrine Society.
  • WPATH Standards of Care 8 (2022) asks for "several years" of persistent distress and a thorough assessment, but sets no requirement that dysphoria began in early childhood. It set no minimum ages for hormones or most surgeries. Age minimums in a 2021 draft were removed before publication. See WPATH.
  • Many US clinics moved towards an "affirmative" model in which a young person's stated identity is accepted rather than explored (see Evidence Reviews: the affirmation model).

Inside the Netherlands

Practice also shifted in the Dutch clinics. At Leiden (2010–2018), the typical age at starting blockers was 15 for trans girls and 16 for trans boys, late in puberty or after it. Twenty adolescents stayed on blockers longer than planned, often because of unstable family situations, autism or depression (Brik et al. 2020). In the 720-person Amsterdam cohort, the median age at starting blockers was 16.0 for those born female (van der Loos et al. 2022). A 20-year review of 1,766 children and adolescents at Amsterdam found a steep rise in referrals, a shift towards females, and rising ages at intake and at the start of blockers (van der Loos et al. 2023, J Sex Med).

What detransitioners describe

Detransitioners who were treated outside the Netherlands often describe the steps the Dutch criteria were meant to ensure as missing: assessments of a few sessions, psychiatric history ignored, and parents told that treatment was urgent.

I wish someone had been able to counter the assertion that PBs are not experimental and have been consistently used for decades. A very deceptive statement because the Dutch protocol hasn't been followed in other countries; it's been radically altered by applying it to a different population. Historically, it was never used when children had a late onset of dysphoria in their teens. —Takeshold, detrans female

I remember being 16 and going to the gender clinic and I was so scared that they were going to gatekeep me. I was so worried that they would be concerned about the fact that I was literally testifying in court against someone who raped me, had an eating disorder, had a history of depression and suicide attempts, had severe lifelong anxiety and panic attacks but they weren't concerned about these things at all. —Admirable_Treacle_97, detrans female

I was prescribed estrogen and puberty blockers when I was 16. Only two hour long appointments with a psychiatrist at Children's hospital then I was given the green light to start hrt. —Dear-Shift-7636, detrans male

These accounts describe treatment that broke the original rules: psychiatric instability, little exploration, and in some cases hormones started together with blockers. See Mental Health and Gender Dysphoria, Trauma and Informed Consent.

Being blocked young: detransitioner and trans accounts

Detransitioners

Some detransitioners were given blockers in early adolescence, close to the age and puberty stage the protocol envisaged. Their accounts focus on how the decision was presented, what was not explored, and what was lost.

One commenter's family had planned on the Dutch protocol by name:

I got blockers at 12 and started a low-dose testosterone then that mimicked male puberty. My family and I had been planning to do the Dutch protocol since I was pretty young. I have very mixed feelings—in some cases it could be worth it, but there are wayyyy too many unknowns. My parents genuinely wanted the best for me and were only given affirmative information and resources. Now, I'm a 15 year old female with a deep voice and masculine face, and I just recently chose to go off blockers and T. I feel like a science experiment, and I'm just basically waiting to see what will happen with my body. —redactedchicken, /r/detrans commenter

Others describe blockers as the first step on a path they were urged to take quickly, so that they would not go through their own puberty:

I socially transitioned when i was 10, was put on Blockers very quickly but only Startes testosterone when i was like 15/16. my expierience was similar to yours, they told me to Act quickly so i do Not Go through female puberty, that was also one of the Main points to lead me to Transition fuhrter, i was just reaffirmed by everyone so i as a small Child thought that it was great up until lately. —Empty_Context222, detrans female

Even though it was my choice and I'm aware that I'm at least partly responsible for it, I'm still so upset that I was given blockers at 14 and Testosterone injections at 16. My brain was not developed enough to fully comprehend the (sometimes irreversible) changes that HRT would bring, and if the therapists would have just tried to actually delve deeper they would have realized that what I mistook as gender dysphoria was actually just deeply rooted trauma and self-hatred. —Luzzenz, detrans female

Some say they were told blockers were harmless, which echoes the "fully reversible" language of the 1996 proposal:

I wanted puberty blockers when I was younger because I heard they were harmless and would help people struggling with their self-image like me. I was never told about any sort of biological damage they could cause. —willow_wind, questioning own transgender status

And some point out that the protocol's own timetable, blockers from 12 until hormones at 16, means years of suppression, not a short pause:

Furthermore, someone would need to be on blockers for 5 years or so between the onset of puberty and the time they're old enough to make an informed choice about transitioning. That can't be considered a short-term course. —bigbeard61, desisted male

Trans people

Trans people who were given blockers early, or wish they had been, often describe them as the treatment that spared them the most distressing and permanent effects of the wrong puberty. In its strongest form, this view says that natal puberty is itself irreversible. Withholding blockers is therefore not a neutral choice, and an adolescent who stops them can still go through their own puberty.

Giving someone a way to not inflict the damage of the wrong puberty is the point of blockers. Give them the opportunity to decide, before the wrong hormones are forced upon them, right? If you won't give someone what they want, don't force them to live through what might very well hurt them. —ZoeyKaisar, trans woman (MTF)

If your 13-year-old is experiencing distress from puberty, puberty blockers can be a safe, reversible option to give him time to explore his identity without the added stress of unwanted physical changes. —Alexzulii, trans man (FTM)

I've known something was there since I was 7 years old, but I didn't know then that being trans was even a thing. As a result, I repressed myself until my early twenties, and was traumatized by a decade of puberty. If I had known was it was then, I wouldn't have suffered so much, as I'm sure I could have convinced my parents to get me on puberty blockers. —Ok_Delay1124, trans woman (MTF)

Not every trans account is as clear-cut. One trans man who got blockers at 11 or 12 was glad of them, but also said he did not regret the part of female puberty he went through:

I totally get this- I don't "regret" female puberty at all. I didn't go through the whole thing, but I remember being exited about boobs and stuff, I'm glad I was able to get on hormone blockers so early (about 11-12) —MISOSOOUPE, trans man (FTM)

Where the accounts meet and diverge

QuestionTrans accountsDetransitioner accounts
What do blockers do?Prevent irreversible changes of the wrong puberty; buy timeStop development during a window that does not come back; not a pause
Is early treatment a benefit?Yes: earlier means less distress and better physical results laterEarly treatment came before they could understand what was being decided, or explore other causes
Were risks explained?Often described as safe and reversibleOften say they were told blockers were harmless
What about the "time to think"?Time to explore identity without distressThe time was used to prepare for the next step, not to question it

Both groups describe the same treatment, in some cases at the same ages, with opposite outcomes. Both describe early adolescence as a time when decisions had to be made under pressure. The disagreement is over which mistake is worse: going through a puberty you did not want, or missing one you later wished you had had. The Dutch studies cannot settle this, because they never followed a group that did not receive blockers and they stopped at around age 20.

What the Dutch clinicians have said since

The Dutch team has defended its original work while warning, at several points, that it should not be applied uncritically to today's patients.

  • 2020: "Some caution is warranted." In a Pediatrics commentary, Annelou de Vries noted that the original protocol required "a presence of gender dysphoria from early childhood on". She noted that adolescents with post-pubertal, adolescent-onset histories "did not yet participate in the early evaluation studies". She said this "raises the question" whether the positive outcomes also apply to adolescents who now "present in overwhelming large numbers", including older ones "possibly without a childhood history". She noted that some case histories describe later-presenting adolescents who eventually detransition, and that systematic studies of discontinuation after hormones or surgery "are lacking at present" (de Vries 2020).
  • 2021: "We don't know whether studies we have done in the past can still be applied to this time." Thomas Steensma of the Amsterdam centre told the Dutch newspaper Algemeen Dagblad that "many more children are registering, and also a different type", with three times as many registrants born female as born male. He said little research existed on blockers and hormones in young people, which is "why it is also seen as experimental". He also criticised clinics abroad for "blindly" adopting the Dutch treatments without researching their own patients (English translation via Voorzij). A few months later he told NRC that there was "no evidence" of a hype, and that the newer female patients were not more or less gender-incongruent than earlier ones (NRC 2021).
  • 2022–2024: defending the studies. De Vries defended the 2011 and 2014 findings against critics (de Vries 2023), and the team has continued to stand by the protocol. They point to their time-trend data, which found no change in the intensity of dysphoria or psychological functioning among Amsterdam referrals from 2000 to 2016, apart from the shift in sex ratio.

The two positions can coexist: the Dutch clinicians maintain that their model works for the patients it was designed for, and that clinics which loosened the criteria are a separate problem. Some detransitioners read the clinicians' warnings as an admission that the evidence never covered people like them.

The authors of the dutch studies are starting to get vocal about how the current affirmation-only system isn't supported by their findings due to the population differences, despite those same studies almost soley being used to justify it. —spare_eye, desisted female

Recent Dutch follow-up data

Continuation of hormones: van der Loos et al. (2022)

The largest recent Dutch study linked Amsterdam clinic records to the national prescription register (van der Loos et al. 2022, Lancet Child & Adolescent Health).

  • Who: 720 people (69% born female) who started blockers before 18 and then added cross-sex hormones.
  • Finding: At the end of 2018, 704 (98%) had a cross-sex hormone prescription; 16 did not.
  • Ages: Median age at starting blockers was 14.1 for those born male and 16.0 for those born female. At the end of follow-up the median age was only about 20 and 19.
  • No predictors: Age, puberty stage, year of first visit and removal of the gonads did not predict stopping.

The authors called the result reassuring. Its limits are significant:

  • A prescription is not a measure of benefit. The study counted an insured prescription on one date. It did not measure whether people took the drugs, or their wellbeing, satisfaction or regret.
  • Follow-up was short. In the adult Amsterdam cohort, regret appeared on average about 11 years after starting hormones, with a range of about 4 to 22 years (Wiepjes et al. 2018). Most participants in the 2022 study had not reached that point.
  • Gonadectomy forces continuation. People whose ovaries or testes have been removed need some sex hormone for life to protect their bones. A continuing prescription does not show that they still support their transition.
  • Only those who reached hormones were counted. Anyone who stopped after blockers alone was excluded.
  • Other data differ. A US military health records study found that about 3 in 10 had stopped hormones within four years (Roberts et al. 2022).

Some trans commenters cite high continuation rates as evidence that adolescents who start treatment rarely change their minds. Detransitioners who discussed the study when it came out asked what the 98% actually measured:

In my mind, the biggest issue would be the reason for continuation. Were participants continuing with treatment because of satisfaction or because they felt they had to continue due to developmental, social, or medical issues. —OnceBitten8240, detrans female

Stopping blockers

Dutch studies report that very few adolescents stop blockers:

  • 1.4% of those who started blockers in the 20-year Amsterdam review stopped, mostly because their dysphoria had gone (van der Loos et al. 2023, J Sex Med).
  • 3.5% (5 of 143) at Leiden stopped because they no longer wanted gender treatment. Their reasons included feeling non-binary, falling in love, and family or personal problems (Brik et al. 2020).

The Leiden authors themselves wrote that the high progression to hormones might reflect eligibility criteria that select adolescents very likely to continue, and that their study could not show whether blockers themselves make persistence more likely.

Other Dutch outcome studies

Other Amsterdam follow-ups found that spine bone density in those born male was still below its pre-treatment level for age after about 12 years of hormones (van der Loos et al. 2023); that none of 29 trans women blocked in early puberty had mature sperm at surgery (de Nie et al. 2022); and that adult regret after gonadectomy was 0.3–0.6%, counted only as restarting birth-sex hormones, with 36% of patients no longer attending (Wiepjes et al. 2018). These are covered on Puberty Blockers, Fertility and Transition Regret.

The Dutch Health Council review (2026)

After two motions in the Dutch parliament, the health minister asked the Health Council of the Netherlands (Gezondheidsraad) to review youth gender care. Its advice, published on 30 June 2026, covers blockers and cross-sex hormones for under-18s but not surgery (Gezondheidsraad 2026). Its main conclusions:

  • Dutch youth gender care is "carefully organised", with an extensive exploratory phase, and fits the Dutch legal framework.
  • The treatments achieve their intended physical effects. There are "indications of some improvement" in mental outcomes, and current data on unintended effects are not cause for concern.
  • Effects on cognition and fertility are insufficiently researched, and long-term data are missing.
  • Dutch studies show 0% to 3.5% stop hormones they started as minors, and found no regret. But the number of people with regret "cannot be properly established" because of short follow-up and "substantial dropout" in the studies. The council also saw signs that some people who stop or regret do not tell their care providers.
  • International practice that refers to the Dutch protocol "is not always in line with" the current Dutch model, and it is unclear whether other countries gave enough attention to exploration and psychological support.

The council did not recommend changing how care is organised, reasoning that doing nothing can also harm mental health. It recommended more exploration of gender questions in general practice and regular mental health care, clearer rules on diagnosis and on assessing a young person's capacity to consent, multicentre studies with follow-up "well into adulthood" in samples that reflect recent referrals, and national standardised monitoring, partly to track stopping, regret and detransition. It also recommended research into the experiences and care needs of people who stop or regret, including outside the specialist gender centres. The Dutch government accepted the advice in October 2026 (Ministry of Health, Welfare and Sport 2026).

The Netherlands has therefore taken a different path from England, Sweden and Finland, which restricted blockers after their own evidence reviews (see Evidence Reviews). The Dutch council's own text accepts many of the gaps critics identified: no long-term data, unknown regret rates, substantial dropout, and patients who leave care without being counted.

Detransitioners who went back to Dutch clinics for help describe a system that had not expected them:

I got in touch with a gender therapist and i had to explain to her why i regretted my transition. Fortunaly the woman who was my therapist was a really sweet woman , but it was very obvious she had no idea that regret was a thing. She told me that only less than 1% had regret , so apparently i was a very interesting case to her. —MoonKitten7, detrans female

What this means

  • Pioneering, but limited. The Dutch studies were the first prospective data on puberty suppression for dysphoria. They were also small, uncontrolled, single-clinic and stopped at about age 20. Their headline findings are contested on checkable grounds: a changed questionnaire, gains that cannot be separated from therapy and maturation, and a final sample that left out those who could not finish the pathway, including one patient who died.
  • The one close replication failed. The British study, with similar criteria, found no psychological improvement, and a re-analysis found a substantial minority got worse.
  • The criteria mattered, and were dropped. The protocol was designed for early-onset, psychologically stable, well-supported adolescents. The patients who drove the rise in referrals after 2012 often fit none of these criteria, and many clinics treated them anyway. The Dutch clinicians, the Cass Review and the Dutch Health Council have all called for research on this newer group.
  • Continuation is not the same as benefit. Recent Dutch data show that nearly everyone who starts blockers continues to hormones, and nearly all are still prescribed hormones around age 20. This does not show they are better off, and does not capture later regret or those who left care.
  • What is unknown. No study has followed Dutch-protocol patients into middle age for mental health, sexual function, fertility, bone fractures or detransition. No study has compared them with similar adolescents who did not receive blockers.
References
  • Abbruzzese, E., Levine, S. B. & Mason, J. W. (2023). The Myth of "Reliable Research" in Pediatric Gender Medicine: A critical evaluation of the Dutch Studies—and research that has followed. Journal of Sex & Marital Therapy, 49(6). source.
  • Biggs, M. (2020). Gender Dysphoria and Psychological Functioning in Adolescents Treated with GnRHa: Comparing Dutch and English Prospective Studies. Archives of Sexual Behavior, 49(7), 2231–2236. source.
  • Biggs, M. (2023). The Dutch Protocol for Juvenile Transsexuals: Origins and Evidence. Journal of Sex & Marital Therapy, 49(4), 348–368. source.
  • Brik, T. et al. (2020). Trajectories of Adolescents Treated with Gonadotropin-Releasing Hormone Analogues for Gender Dysphoria. Archives of Sexual Behavior. study page, source.
  • Carmichael, P. et al. (2021). Short-term outcomes of pubertal suppression in a selected cohort of 12 to 15 year old young people with persistent gender dysphoria in the UK. PLOS ONE. study page, source.
  • Cass, H. (2024). Independent review of gender identity services for children and young people: Final report. study page, source.
  • Cohen-Kettenis, P. T. & van Goozen, S. H. M. (1998). Pubertal delay as an aid in diagnosis and treatment of a transsexual adolescent. European Child & Adolescent Psychiatry, 7, 246–248. source.
  • Cohen-Kettenis, P. T., Delemarre-van de Waal, H. A. & Gooren, L. J. G. (2008). The treatment of adolescent transsexuals: changing insights. Journal of Sexual Medicine, 5(8), 1892–1897. source.
  • Coleman, E. et al. (2022). Standards of Care for the Health of Transgender and Gender Diverse People, Version 8. International Journal of Transgender Health. study page, source.
  • de Nie, I. et al. (2022). Histological study on the influence of puberty suppression and hormonal treatment on developing germ cells in transgender women. Human Reproduction. study page, source.
  • de Vries, A. L. C. et al. (2011). Puberty suppression in adolescents with gender identity disorder: a prospective follow-up study. Journal of Sexual Medicine. study page, source.
  • de Vries, A. L. C., McGuire, J. K., Steensma, T. D., Wagenaar, E. C. F., Doreleijers, T. A. H. & Cohen-Kettenis, P. T. (2014). Young adult psychological outcome after puberty suppression and gender reassignment. Pediatrics, 134(4), 696–704. source.
  • de Vries, A. L. C. (2020). Challenges in Timing Puberty Suppression for Gender-Nonconforming Adolescents. Pediatrics, 146(4), e2020010611. source.
  • de Vries, A. L. C. (2023). Ensuring Care for Transgender Adolescents Who Need It: Response to 'Reconsidering Informed Consent for Trans-Identified Children, Adolescents and Young Adults'. Journal of Sex & Marital Therapy, 49(1), 108–114. source.
  • Delemarre-van de Waal, H. A. & Cohen-Kettenis, P. T. (2006). Clinical management of gender identity disorder in adolescents: a protocol on psychological and paediatric endocrinology aspects. European Journal of Endocrinology, 155(Suppl 1), S131–S137. source.
  • Gezondheidsraad (Health Council of the Netherlands) (2026). Transgenderzorg voor jongeren (Transgender care for young people). Publication 2026/12. source.
  • Ministry of Health, Welfare and Sport (2026). Beleidsreactie op advies Transgenderzorg voor jongeren (Government response to the Health Council advice). source.
  • Gooren, L. & Delemarre-van de Waal, H. (1996). The feasibility of endocrine interventions in juvenile transsexuals. Journal of Psychology & Human Sexuality, 8(4), 69–74. source.
  • Hembree, W. C. et al. (2017). Endocrine Treatment of Gender-Dysphoric/Gender-Incongruent Persons: An Endocrine Society Clinical Practice Guideline. Journal of Clinical Endocrinology & Metabolism. study page, source.
  • Kaltiala-Heino, R. et al. (2015). Two years of gender identity service for minors: overrepresentation of natal girls with severe problems in adolescent development. Child and Adolescent Psychiatry and Mental Health. study page, source.
  • McPherson, S. & Freedman, D. E. P. (2024). Psychological Outcomes of 12–15-Year-Olds with Gender Dysphoria Receiving Pubertal Suppression in the UK: Assessing Reliable and Clinically Significant Change. Journal of Sex & Marital Therapy, 50(3), 315–325. source.
  • National Institute for Health and Care Excellence (2020). Evidence review: Gonadotrophin releasing hormone analogues for children and adolescents with gender dysphoria. source.
  • Negenborn, V. L. et al. (2017). Lethal Necrotizing Cellulitis Caused by ESBL-Producing E. Coli after Laparoscopic Intestinal Vaginoplasty. Journal of Pediatric and Adolescent Gynecology, 30(1). source.
  • NRC (2021). Zijn de zorgen over transjongeren bij de genderpoli terecht? (interview with Thomas Steensma). source.
  • Olson-Kennedy, J. et al. (2025). Mental and Emotional Health of Youth after 24 months of Gender-Affirming Medical Care Initiated with Pubertal Suppression. medRxiv (preprint). study page, source.
  • Roberts, C. M. et al. (2022). Continuation of Gender-affirming Hormones Among Transgender Adolescents and Adults. Journal of Clinical Endocrinology & Metabolism. study page, source.
  • Teteleptal, B. (2021). Interview with Thomas Steensma, Algemeen Dagblad, 27 February 2021 (English translation by Voorzij). source.
  • van der Loos, M. A. T. C. et al. (2022). Continuation of gender-affirming hormones in transgender people starting puberty suppression in adolescence: a cohort study in the Netherlands. Lancet Child & Adolescent Health. study page, source.
  • van der Loos, M. A. T. C. et al. (2023). Children and adolescents in the Amsterdam Cohort of Gender Dysphoria: trends in diagnostic- and treatment trajectories during the first 20 years of the Dutch Protocol. Journal of Sexual Medicine, 20(3), 398–409. source.
  • van der Loos, M. A. T. C. et al. (2023). Bone Mineral Density in Transgender Adolescents Treated With Puberty Suppression and Subsequent Gender-Affirming Hormones. JAMA Pediatrics. study page, source.
  • van der Loos, M. A. T. C. (2024). The Dutch Protocol: Coming of Age (doctoral thesis, Vrije Universiteit Amsterdam). source.
  • Wiepjes, C. M. et al. (2018). The Amsterdam Cohort of Gender Dysphoria Study (1972–2015): Trends in Prevalence, Treatment, and Regrets. Journal of Sexual Medicine. study page, source.

Last updated:

Suggest an Article or an Improvement

Spotted something missing, unclear or wrong on this page, or have an idea for a related article? Let us know and we'll take a look.

Only if you'd like a reply

Related pages: